Toll Free: 1-888-928-9744

Ewing Sarcoma - Pipeline Review, H1 2017

Published: May, 2017 | Pages: 255 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Ewing Sarcoma - Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Ewing Sarcoma - Pipeline Review, H1 2017, provides an overview of the Ewing Sarcoma (Oncology) pipeline landscape.

Ewing's sarcoma is a primary bone cancer that affects mainly children and adolescents. Ewing's sarcoma can occur any time during childhood and young adulthood, but usually develops during puberty, when bones are growing rapidly. There are few symptoms. The most common is pain and occasionally swelling at the site of the tumor. Children may also break a bone at the site of the tumor after a seemingly minor injury. 

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Ewing Sarcoma - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Ewing Sarcoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Ewing Sarcoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Ewing Sarcoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 10, 8, 21 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 2, 2 and 2 molecules, respectively.

Ewing Sarcoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Ewing Sarcoma (Oncology).
- The pipeline guide reviews pipeline therapeutics for Ewing Sarcoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources. 
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Ewing Sarcoma (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Ewing Sarcoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects. 
- The pipeline guide reviews latest news related to pipeline therapeutics for Ewing Sarcoma (Oncology)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Ewing Sarcoma (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Ewing Sarcoma (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
 Table of Contents
Table of Contents 2 Introduction 4 Ewing Sarcoma - Overview 5 Ewing Sarcoma - Therapeutics Development 6 Ewing Sarcoma - Therapeutics Assessment 14 Ewing Sarcoma - Companies Involved in Therapeutics Development 24 Ewing Sarcoma - Drug Profiles 38 Ewing Sarcoma - Dormant Projects 239 Ewing Sarcoma - Discontinued Products 240 Ewing Sarcoma - Product Development Milestones 241 Appendix 249
List of Tables
Number of Products under Development for Ewing Sarcoma, H1 2017 11 Number of Products under Development by Companies, H1 2017 13 Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017 14 Number of Products under Development by Universities/Institutes, H1 2017 15 Products under Development by Companies, H1 2017 16 Products under Development by Companies, H1 2017 (Contd..1), H1 2017 17 Products under Development by Universities/Institutes, H1 2017 18 Number of Products by Stage and Target, H1 2017 20 Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017 21 Number of Products by Stage and Mechanism of Action, H1 2017 23 Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017 24 Number of Products by Stage and Route of Administration, H1 2017 26 Number of Products by Stage and Molecule Type, H1 2017 28 Ewing Sarcoma - Pipeline by Amgen Inc, H1 2017 29 Ewing Sarcoma - Pipeline by Astellas Pharma Inc, H1 2017 29 Ewing Sarcoma - Pipeline by Bristol-Myers Squibb Company, H1 2017 30 Ewing Sarcoma - Pipeline by Cebiotex SL, H1 2017 30 Ewing Sarcoma - Pipeline by Celgene Corp, H1 2017 31 Ewing Sarcoma - Pipeline by Celldex Therapeutics Inc, H1 2017 32 Ewing Sarcoma - Pipeline by CytRx Corp, H1 2017 32 Ewing Sarcoma - Pipeline by EntreChem SL, H1 2017 33 Ewing Sarcoma - Pipeline by Gradalis Inc, H1 2017 33 Ewing Sarcoma - Pipeline by Incyte Corp, H1 2017 34 Ewing Sarcoma - Pipeline by Leadiant Biosciences Inc, H1 2017 35 Ewing Sarcoma - Pipeline by MacroGenics Inc, H1 2017 35 Ewing Sarcoma - Pipeline by Merck & Co Inc, H1 2017 36 Ewing Sarcoma - Pipeline by Merrimack Pharmaceuticals Inc, H1 2017 36 Ewing Sarcoma - Pipeline by NanoSmart Pharmaceuticals Inc, H1 2017 37 Ewing Sarcoma - Pipeline by NantKwest Inc, H1 2017 37 Ewing Sarcoma - Pipeline by Novartis AG, H1 2017 38 Ewing Sarcoma - Pipeline by Oncomatryx Biopharma SL, H1 2017 38 Ewing Sarcoma - Pipeline by Oncternal Therapeutics Inc, H1 2017 39 Ewing Sarcoma - Pipeline by Pfizer Inc, H1 2017 39 Ewing Sarcoma - Pipeline by Pharma Mar SA, H1 2017 40 Ewing Sarcoma - Pipeline by Recombio SL, H1 2017 41 Ewing Sarcoma - Pipeline by Shionogi & Co Ltd, H1 2017 41 Ewing Sarcoma - Pipeline by Tarveda Therapeutics Inc, H1 2017 42 Ewing Sarcoma - Pipeline by Tesaro Inc, H1 2017 42 Ewing Sarcoma - Dormant Projects, H1 2017 244 Ewing Sarcoma - Discontinued Products, H1 2017 245



                                

To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $2000
Multi User - US $4000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify